Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986089 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAD Panel 1:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration |
| SAD Panel 2:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration |
| SAD Panel 3:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration |
| SAD Panel 4:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration |
| SAD Panel 5:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration |
| MAD Panel 1:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 multiple subcutaneous administrations weekly |
| MAD Panel 2:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly |
| MAD Panel 3:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly |
| MAD Panel 4:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly |
| MAD Panel 5:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in multiple subcutaneous administration every 2 weeks OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly |
| MAD Panel 6:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly |
| MAD Panel 7:BMS-986089/Placebo | EXPERIMENTAL | BMS-986089 a single subcutaneous administrations weekly OR Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks |
| Name | Type | Description |
|---|---|---|
| BMS-986089 | DRUG | - |
| Placebo matching with BMS-986089 | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal medical history, physical examination, ECGs and clinical laboratory determinations * Men and...
BMS-986089 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease indications for BMS-986089 have not been disclosed, and the compound remains in early clinical development.
BMS-986089 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche holds the development program for this small molecule asset.
BMS-986089 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
BMS-986089 was evaluated in a single Phase 1 trial, NCT02145234, titled a placebo-controlled, single and multiple ascending subcutaneous dose study of safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects. The trial enrolled 140 participants in the United States, was randomized, double-blind, and controlled, and is now completed.
BMS-986089 has been studied in healthy adult volunteers rather than in patients with a specific disease. Its intended therapeutic indications have not been disclosed, so no approved or investigational use in a particular condition can be stated.
BMS-986089 was given by subcutaneous injection in its Phase 1 trial, NCT02145234. That study tested single and multiple ascending doses against placebo in 140 healthy adult subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.